Geoffrey Hodge

Geoffrey Hodge is the CEO of SOTIO Biotech Inc., a Cambridge, MA (US) that is focused on the development of novel cell therapies to treat solid tumors. He has over 30 years of experience in the biotechnology industry, providing bioprocessing technical solutions for companies including GE Healthcare Life Sciences (Cytiva), Millennium Pharmaceuticals (Takeda), Genetics Institute (Wyeth/Pfizer) and Alpha-Beta Technology. He is an inventor on more than a dozen bioprocess equipment and technology patents.

Prior to SOTIO, Geoff was Chief Technical Officer at Unum Therapeutics, where he managed all technical operations for the company including process and analytical development, manufacturing, logistics and quality for clinical phase viral vector and T-cell processes. He was previously a co-founder of Xcellerex, a company pioneering single-use bioreactors, mixers, facilities, and GMP manufacturing services. He served as an operations leader at GE Healthcare Life Sciences after GE acquired Xcellerex. Geoff holds an M.S. in Biotechnology from Worcester Polytechnic Institute and Bachelor’s degree in Biology from Colgate University.